Number of the records: 1

Amphipilic compounds with neuroprotective properties

SYSNO ASEP	0533018
Document Type	P - Patent
R&D Document Type	Patent or other outcome protected by special legislation
Title	Amphipilic compounds with neuroprotective properties
Author(s)	Chodounská, Hana (UOCHB-X)_{RID, ORCID} Jahn, Ullrich (UOCHB-X)_ORCID Kapras, Vojtěch (UOCHB-X) Kudová, Eva (UOCHB-X)_{RID, ORCID} Valeš, Karel (FGU-C)_{RID, ORCID, SAI} Vyklický ml., Ladislav (FGU-C)_{RID, ORCID, SAI}
Year of issue	2020
Possible third party use of the result	A - Pro využití výsledku jiným subjektem je vždy nutné nabytí licence
Royalty requested	A - Poskytovatel licence požaduje licenční poplatek
Patent no. or utility model no. or industrial design no.	CA3013725
Date of the patent acceptance	30.06.2020
Name of the patent owner	Ústav organické chemie a biochemie AV ČR, v. v. i. - Fyziologický ústav AV ČR, v. v. i
Code of the issuer name	CA001 - Canadian Intellectual Property Office (CIPO) Gatineau, Québec
Current use	A - Pouze udělený (dosud nevyužívaný) patent nebo patent využívaný jeho vlastníkem
Language	eng - English
Keywords	steroid ; NMDA receptor ; neuroprotective
Subject RIV	CC - Organic Chemistry
OECD category	Organic chemistry
Subject RIV - cooperation	Institute of Physiology - Pharmacology ; Medidal Chemistry
R&D Projects	TE01020028 GA TA ČR - Technology Agency of the Czech Republic (TA ČR)
	GBP304/12/G069 GA ČR - Czech Science Foundation (CSF)
Institutional support	UOCHB-X - RVO:61388963 ; FGU-C - RVO:67985823
Annotation	The present invention provides amphiphilic compounds with tetradecahydrophenanthrene skeleton of general formula I, and their enantiomers, wherein R1, R2, 115, R4 and R5 are as defined herein, exhibiting neuroprotective effects, their use as medicaments for treating neuropsychiatric disorders associated with an imbalance in glutamatergic neurotransmitter system, such as ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, post-traumatic stress disorder and diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain , addiction, multiple sclerosis, epilepsy, glioma, and a pharmaceutical composition containing said compound.
Workplace	Institute of Organic Chemistry and Biochemistry
Contact	asep@uochb.cas.cz ; Kateřina Šperková, Tel.: 232 002 584 ; Jana Procházková, Tel.: 220 183 418
Year of Publishing	2021
Electronic address	https://worldwide.espacenet.com/publicationDetails/originalDocument?CC=CA&NR=3013725C&KC=C&FT=D&ND=4&date=20200630&DB=&locale=en_EP

Number of the records: 1